oral prostaglandin F receptor GCPR antagonist

to treat IPF, in vivo efficacy in fibrosis model

from ~3M cmpd cell-based HTS and opt.

J. Med. Chem., Oct. 22, 2020 issue

Bayer AG, Wuppertal, DE

Structure of BAY-6672, a potent, selective and orally bioavailable prostanoid FP receptor antagonist

BAY-6672 (Bayer oral in vivo prostaglandin F receptor GCPR antagonist)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: